Takayuki Nakayama
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Living-donor Kidney Transplantation After Resection of Mixed Epithelial and Stromal Tumor: A Positive Outcome Despite Not Observing the Recommended Waiting Period.
Journal: Cancer diagnosis & prognosis
Published: April 13, 2026
Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker.
Journal: Targeted oncology
Published: February 28, 2026
Belzutifan for Metastatic TFE3-Rearranged Renal Cell Carcinoma With Pulmonary Metastases: A Case Report.
Journal: IJU case reports
Published: February 28, 2026
Pathologic Complete Response After Enfortumab Vedotin Plus Pembrolizumab in Node-positive Upper Tract Urothelial Carcinoma.
Journal: In vivo (Athens, Greece)
Published: January 20, 2026
Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma.
Journal: Japanese journal of clinical oncology
Published: January 11, 2026
Midterm Outcomes of Combination Therapy With Immune Checkpoint Inhibitors and VEGFR-TKIs in Real-World Patients With Advanced Renal Cell Carcinoma.
Journal: International journal of urology : official journal of the Japanese Urological Association
Published: November 25, 2025
Non-Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors.
Journal: Molecular cancer research : MCR
Published: August 27, 2025
Safety of Enfortumab Vedotin Plus Pembrolizumab in Hemodialysis Patients With Metastatic Urothelial Carcinoma: Case Report.
Journal: Cancer diagnosis & prognosis
Published: July 19, 2025
Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma.
Journal: Japanese journal of clinical oncology
Published: June 28, 2025
Impact of first-line dual immuno-oncology combination therapy versus immuno-oncology plus tyrosine kinase inhibitor on outcomes of second-line VEGFR-TKI in advanced RCC: a real-world multi-institutional analysis.
Journal: International urology and nephrology
Published: May 15, 2025
Effect of age on treatment outcomes of first-line immune checkpoint inhibitor combination therapy for previously untreated advanced renal cell carcinoma.
Journal: Geriatrics & gerontology international
Published: March 26, 2025
Comparison of real-world outcomes between nivolumab plus ipilimumab and lenvatinib plus pembrolizumab or nivolumab plus cabozantinib combination therapies for previously untreated advanced renal cell carcinoma.
Journal: Urologic oncology
Published: October 26, 2024
Last Updated: 09/26/2026